Schizonil 1mg Tablet

Interactions

Drug :- adsorbent antidiarrheals, aluminum- and magnesium-containing antacids: Possibly inhibited absorption of oral trifluoperazine.

amantadine, anticholinergics, antidyskinetics, antihistamines: Possibly intensified adverse.

anticholinergic effects, increased risk of trifluoperazine-induced hyperpyrexia amphetamines: Decreased stimulant effect.

of amphetamines, decreased antipsychotic effect of trifluoperazine anticonvulsants: Lowered seizure threshold.

antithyroid drugs: Increased risk of agranulocytosis.

apomorphine: Possibly decreased emetic response to apomorphine, additive CNS depression.

appetite suppressants: Decreased effects of appetite suppressants.

astemizole, cisapride, disopyramide, erythromycin, pimozide, probucol, procainamide, quinidine: Prolonged QT interval, increased risk of ventricular tachycardia.

beta blockers: Increased blood levels of both drugs, possibly leading to additive hypotensive.

effect, arrhythmias, irreversible retinopathy, and tardive dyskinesia bromocriptine: Impaired therapeutic effects of bromocriptine.

CNS depressants: Additive CNS depression.

ephedrine, metaraminol: Decreased vasopressor response to ephedrine.

epinephrine: Blocked alpha-adrenergic effects of epinephrine.

extrapyramidal reaction-causing drugs droperidol, haloperidol, metoclopramide, metyrosine, risperidone: Increased severity and frequency of extrapyramidal reactions.

hepatotoxic drugs: Increased risk of hepatotoxicity.

hypotension-producing drugs: Possibly severe hypotension with syncope.

levodopa: Decreased antidyskinetic effect of levodopa.

lithium: Reduced absorption of oral trifluoperazine, possibly encephalopathy and additive extrapyramidal effects.

MAO inhibitors, maprotiline, tricyclic antidepressants: Possibly prolonged and intensified sedative and anticholinergic effects, increased blood level of antidepressants, impaired trifluoperazine metabolism, increased risk of neuroleptic malignant syndrome.

mephentermine: Decreased antipsychotic effect of trifluoperazine and vasopressor effect of mephentermine.

methoxamine, phenylephrine: Decreased vasopressor effect and shortened duration of action of these drugs.

metrizamide: Increased risk of seizures.

opioid analgesics: Increased risk of CNS and respiratory depression, orthostatic hypotension, severe constipation, and urine retention.

ototoxic drugs: Possibly masking of some symptoms of ototoxicity, such as dizziness, tinnitus, and vertigo.

phenytoin: Lowered seizure threshold, inhibited phenytoin metabolism, possibly leading to phenytoin toxicity.

photosensitizing drugs: Possibly additive photosensitivity and intraocular photochemical damage to choroid, lens, or retina.

thiazide diuretics: Possibly hyponatremia and water intoxication.

Activity :- alcohol use: Increased CNS and respiratory depression, increased hypotensive effect.